Background {#Sec1}
==========

Asthma is a common chronic inflammatory disease of the airways \[[@CR1]\], which leads to variable or even persistent airflow limitation. The main symptoms are dyspnoea (shortness of breath), wheezing, chronic cough and chest tightness. The prevalence for asthma in humans varies worldwide affecting 1 to 18% of any investigated population \[[@CR1]\]. Women are more often affected by asthma. The mechanisms underlying the gender differences in asthma prevalence are still under investigation but refer mostly to hormonal differences and differences in lung capacity \[[@CR2]\].

In this review article we will highlight the role of sex hormones in asthma pathogenesis using data from epidemiological, clinical and animal model studies. The basis of our systematic and thorough literature search is listed in Table [1](#Tab1){ref-type="table"} with keywords and selection criteria.Table 1Database, keywords and selection criteria for literature search on gender aspects in bronchial asthmaSystematic Literature Search^a^DatabaseBiosis, Embase, International Pharmaceutical Abstracts, MedlineSelection CriteriaAsthma Gender Epidemiologyfrom 2003Asthma Gender PathophysiologyAsthma Gender SymptomsAsthma Gender DiagnosticsAsthma Gender TherapyAsthma Sex Hormones1995--2003Role of IgE in Menopausal AsthmaTherapeutic Response to Omalizumab and Gender-specific Differences^a^Update for secondary publication until 2017

Epidemiology of bronchial asthma {#Sec2}
================================

While bronchial asthma affects about 300 million people worldwide, asthma incidence and severity are higher in women than in men, and highest in women between the 4th and 6th decade. During childhood, boys have nearly twice the risk of developing asthma over girls \[[@CR3], [@CR4]\]. During adulthood there is a shift to a female predominance, which affects mainly non-atopic asthma \[[@CR5]\] (Table [2](#Tab2){ref-type="table"}). In the elderly, the gender-related differences decrease \[[@CR6]\].Table 2Excerpt of studies on asthma epidemiology (ref 5, 6, 8), asthma symptoms (female sex hormones: ref. 33, 38, 40, 45; gender specific: ref. 52, 53) and asthma therapy (ref 61, 62)Trial designResultsReference5128 subjects\
Cohort studyAsthma incidence higher in women than men; female predominance stronger in non-sensitized adults\[[@CR5]\]1226 asthmatic patients\
Cross-sectional surveyYounger women have lower quality of life and less asthma control than men\[[@CR6]\]8607 subjects\
Cohort studyObesity and asthma are correlated in 6--7 year old children but not in 13--14 year old teenagers\[[@CR8]\]571 women\
Population-based cohort studyVariation of bronchial hyperreactivity during menstruation due to hormonal influences\[[@CR33]\]2322 women\
Population-based cohort studyThe odds of new onset asthma are increased in early postmenopausal women\[[@CR38]\]2206 women\
Population-based cohort studyHormone replacement therapy and overweight increase the risk of asthma\[[@CR40]\]1438 women\
Population-based cohort studyLung function decline is more rapid among post-menopausal women; respiratory health often deteriorates during reproductive aging\[[@CR45]\]1248 children\
Population-based study;\
Secondary analysisGirls with asthma have higher physical tobacco dependence scores compared to girls without asthma\[[@CR52]\]3700 non-asthmatics\
746 asthmatics\
Observational cohort studyAsthma is associated with increased risk of new onset chronic migraine; higher risk with higher number of respiratory symptoms\[[@CR53]\]122 asthmatics\
Population-based studyNo effect of inhaled corticosteroids on the decline of lung function in women compared to men\[[@CR61]\]194 asthmatics\
Randomized, controlled trialMontelukast decreased the risk of worsened asthma with greater benefit in young boys and older girls\[[@CR62]\]

In childhood, obesity, regardless of physical fitness, is associated with higher asthma prevalence and morbidity in girls, but not in boys \[[@CR7]\]. In girls older than 11 years and women, asthma is five to seven times more common in obese people compared to those of normal weight \[[@CR8], [@CR9]\]. A meta-analysis showed an increased incidence of asthma in adipose, and especially in obese women \[[@CR10]\]. In addition, pathophysiological abnormalities can be observed: blood eosinophilia seems to be more prominent in asthmatic girls \[[@CR11]\], but in adipose asthmatic girls a higher prevalence of non-eosinophilic asthma (60.0%) compared to corresponding boys (30.8%) is the case \[[@CR12]\].

Severe asthma affects primarily boys before and at school entry age as well as women around the time of  menopause \[[@CR13]\]. Women also develop "corticosteroid-resistant" or difficult-to-treat asthma, more often than men \[[@CR14]\].

There are also differences in the age-standardized mortality rates, with asthma affecting more women than men (1,37/100.000 compared to 1,16/100.000) \[[@CR15]\]. Women (over 65 years) show a 44% higher asthma mortality than men. Black women in the US show the highest mortality rates due to asthma \[[@CR16]\].

Pathophysiology: Role of sex hormones and their receptors {#Sec3}
=========================================================

Oestrogen receptors are found on numerous immunoregulatory cells, and oestrogen influences immunological responses in the direction of allergy development \[[@CR14]\]. Allergic sensitization --- as demonstrated at least in animal models --- is favoured not only by endogenous oestrogens but also by xeno-oestrogens from environmental pollutants such as bisphenol A and phthalates \[[@CR17]\]. The effects of sex hormones on asthma symptoms and progression are complex and seem to be particularly associated with the fluctuation dynamics of the hormonal levels \[[@CR18]\]. The known pathophysiological effects of sex hormones on asthma are shown in Fig. [1](#Fig1){ref-type="fig"} \[[@CR19]\].Fig. 1Sex steroid effects on bronchial asthma. It is recognized that asthma is a multifactorial disease involving the effects of allergic, infectious and environmental triggers on both the immune system and structural cells of the bronchial airway. Overall, inflammation drives structural and functional airway obstruction leading to epithelial thickening, increased mucus production, proliferation of epithelial, smooth muscle and fibroblast cells, remodelling of the extracellular matrix and overall airway hyperreactivity and fibrosis. Here, studies to-date suggest complex effects of oestrogen vs. progesterone vs. testosterone on relevant cell types, involving both cooperative vs. opposing effects of the different sex steroids within a cell type, but not necessarily across cell types. For example, dendritic cells, mast cells, CD4+ T lymphocytes (Th2), and eosinophils are particularly important. The effects of oestrogen (E), progesterone (P), or testosterone (T) on these immune cells can vary substantially, particularly in the context of concentration, timing and duration \[[@CR19]\]

Testosterone and its metabolites contribute to the physiological balance between autoimmunity and protective immunity by maintaining regulatory T cells. Testosterone has immunosuppressive effects and is probably also protective against immuno-inflammatory processes that trigger asthma \[[@CR20]\]. This notion is supported by recent animal studies showing that male --- but not female --- mice were protected from allergic airway inflammation \[[@CR21]\]. The protective effect was derived from androgen-receptor-mediated inhibition of innate immune cells type 2 (ILC2) that are key players of type 2 inflammatory responses \[[@CR21]\].

In men, asthma morbidity remains relatively stable from puberty to the age-related drop in serum testosterone levels, which subsequently increases the risk of asthmatic impairment \[[@CR22]\]. Previous observations provide evidence for an improvement in asthma symptoms under testosterone intake in women \[[@CR23]\]. Testosterone thus appears to have asthma-suppressive effects, and the less virilising dehydroepiandrosterone (DHEA) as a sulphate (DHEAS), could be helpful in the therapy of premenstrual and severe asthma. Monitoring of DHEA serum level and substitution at deficient levels could therefore be considered for unstable asthmatic patients. However, further studies are necessary \[[@CR24], [@CR25]\].

Symptoms in relation to female sex hormones {#Sec4}
===========================================

The clinical manifestation of asthma is different between women and men \[[@CR26]\]. Women report more pronounced symptoms, which seem to change with the various life stages such as menstruation, pregnancy and menopause and in association with female sex hormone levels \[[@CR2]\]. These hormones cause differences in the clinical manifestation of asthma. Thus, oestrogen promotes bronchial hyperreactivity, and both FEV1 and exhaled nitric oxide (NO) show a cycle-dependent course \[[@CR27]\]. Twenty to forty percent (20--40%) of premenopausal women suffer from pre- or peri-menstrual asthma (PMA) and experience an exacerbation in the week preceding menstruation \[[@CR18], [@CR28]\], based on increased inflammation in the bronchi. This effect seems to be mediated by progesterone rather than by oestrogen \[[@CR28]\]. PMA is less likely to be associated with atopy, but more frequently with aspirin sensitivity and poorer pulmonary function \[[@CR29]\]. Currently the main cause for PMA is considered to be the dynamics or fluctuation rather than the absolute hormone levels, particularly of oestrogen \[[@CR18], [@CR30]\].

The value of hormone (substitution) therapy in women with existing asthma, and possibly also for the treatment of asthma, has so far been critically assessed and requires further studies \[[@CR31]\]. Clinical observations and therapeutic trials showed positive effects of hormone therapy on asthma symptoms in severe perimenstrual asthma \[[@CR18], [@CR32]\], while both positive \[[@CR33], [@CR34]\] and adverse effects \[[@CR35]\] were observed in milder and stable asthma (Table [2](#Tab2){ref-type="table"}). It seems that the effects of oestrogen and progesterone on asthma cannot be described by a simple dose-response relationship \[[@CR30]\].

During pregnancy, asthma can change its manifestation \[[@CR36]\]. About one-third of women show improved asthma symptoms, one third show no change, and one third show deterioration. Asthma symptoms, which are difficult to control before pregnancy, can (but do not need to) increase even more during pregnancy. Earlier evidence that the extent of asthma symptoms is influenced by the sex of the child, with female foetuses being more frequently associated with worse asthma control, has not been confirmed \[[@CR37]\].

In menopausal women, the risk of emergence of (mostly non-allergic) asthma generally increases \[[@CR38], [@CR39]\]. At the same time, oestrogen substitution with a body mass index (BMI) \<30 seems to correlate with an increased risk. However, data on this topic are incongruent \[[@CR40]--[@CR44]\]. Irrespective of the presence of asthma, current data show a disproportionate loss of pulmonary function in peri/postmenopausal women compared to the age-associated decrease. The forced vital capacity (FVC) is more affected than the forced expiratory volume in one second (FEV1), which indicates a restrictive component. Oestrogen-deficit associated osteoporosis, leading to height reduction of the thoracic spine, seems to be partially involved in this restrictive reduction of pulmonary function \[[@CR45]\] (Table [2](#Tab2){ref-type="table"}). These changes in pulmonary function could contribute to clinically perceived asthma deterioration in menopausal women \[[@CR45]\].

Gender-specific symptoms {#Sec5}
========================

Women are more likely to suffer from coughing and wheezing, particularly at a young age, and the age-dependent decrease in bronchial hyperreactivity is less pronounced than in men. In contrast, men report symptoms during the night more frequently \[[@CR46]\].

Men with non-allergic "intrinsic asthma" statistically display higher markers of eosinophilic airway inflammation and suffer more often from nasal polyposis than women \[[@CR47]\]. There are different hypotheses explaining the gender-specific differences in asthma symptoms. Thus, a different perception of bronchial obstruction could be present in women compared to men. This hypothesis is supported by a consistently higher indication of dyspnoea by women compared to men, referring to the same percentage of FEV1, regardless of whether it is a small or large limitation of lung function in absolute terms \[[@CR48]\]. Further hypotheses regarding the different symptoms between men and women take into account the lower inspiratory muscle strength as well as increased bronchial hyperreactivity in women compared to men. In dealing with their inhalation devices, women make mistakes more often \[[@CR49]\].

Another gender difference relates to cigarette smoke, as women are more susceptible to cigarette smoke than men \[[@CR50], [@CR51]\]. Noticeably, girls with asthma who begin to smoke develop physical tobacco dependency much faster than girls without asthma. These differences do not seem to exist in boys \[[@CR52]\] (Table [2](#Tab2){ref-type="table"}).

In a study with migraine patients (gender distribution in migraine about 3:1 to the disadvantage of the female gender) the group suffering from asthma showed twice the risk of transition from episodic to chronic migraine, compared to non-asthmatics. This was statistically highly significant in the subgroup of patients with severe asthma (aOR 3,3) \[[@CR19]\]. Thus, a similar correlation of disease severity can be observed to that of migraine patients with depression as comorbidity. The described migraine- asthma- correlation predominantly affects girls and women \[[@CR19], [@CR53]\].

An essential differential diagnosis of asthma --- especially with unstable symptomatology --- is a "vocal cord dysfunction (VCD)" or "inducible laryngeal obstruction (ILO)" \[[@CR54]\]. In women and girls this dysfunction occurs about 4 to 5 times more frequently than in men and boys, and often leads to unnecessary, long-term adverse effects of therapeutic interventions (especially high dosed administration of systemic glucocorticosteroids) \[[@CR55]\]. Further diagnostic and therapeutic difficulties can arise from the fact that about half of the VCD patients suffer from both classical (often severe) asthma and a vocal cord dysfunction.

Furthermore, episodes of functional, psycho-vegetatively induced hyperinflation of the lungs due to a shift of the physiological inspiration/expiration proportion seem to be more frequently observed in girls and women, which are often misinterpreted as symptoms of asthma (\[[@CR56]\] first-hand experience of corresponding author). These episodes often lead to unnecessary and ultimately unsuccessful medication-based asthma treatment. In this case, as with VCD, breathing therapies are primarily useful, if necessary, supplemented by psychotherapeutic intervention \[[@CR55]\].

In summary, women are more likely to have specific asthma symptoms, such as restriction of activity and shortness of breath, and they have a lower asthma-related quality of life \[[@CR26], [@CR57]\].

Therapy of bronchial asthma: Gender aspects {#Sec6}
===========================================

Asthma is frequently underdiagnosed in women, and asthmatic women are less likely to receive therapy compared to asthmatic men (across all age groups) \[[@CR46]\]. This observation was recently also reported in adolescent athletes \[[@CR58]\]. Instead of topical steroids, women receive psychopharmaceuticals more frequently than men \[[@CR46]\]. Women are more likely to visit their doctor unscheduled and they need emergency medicine more frequently than men \[[@CR49]\]. It seems that the female gender is an independent risk factor for severe asthma exacerbation \[[@CR49]\]. Despite improved lung function and less hypercapnia, emergency hospitalization is more common in women and they need longer hospital stays than men \[[@CR59]\]. However, men have a lower therapeutic adherence in the application of their asthma therapy than women \[[@CR49], [@CR60]\].

For symptomatic asthma medication, such as ß2-sympathomimetics, there are no large studies showing a different effect on women or men. Concerning inhaled steroids, there are indications that in the case of "native asthmatics", who have never been smokers, the increase of FEV1 in relation to vital capacity is significantly higher in men than in women \[[@CR61]\] (Table [2](#Tab2){ref-type="table"}).

Concerning the leukotriene antagonist Montelukast, it has been shown that asthma symptoms significantly improved in treated boys 2 to 9 years of age, but not in girls in the same age group. In the age group of 10- to 14-year-olds, the girls showed a much better response in comparison to the boys \[[@CR62]\]. So the take-home message can be: Montelukast is effective in very young boys and somewhat older girls.

For biologicals such as omalizumab and mepolizumab, no prospectively collected gender-specific data are available on the therapy of asthma. For omalizumab, retrospective analyses have been published on the therapy of severe persistent asthma as well as chronic treatment-resistant urticaria, which showed no difference in the therapeutic response of women and men \[[@CR63], [@CR64]\].

Summary {#Sec7}
=======

What we know from epidemiology {#Sec8}
------------------------------

Childhood: boys have twice the risk of developing asthmaAdulthood: shift to a female predominance

What we assume based on animal studies and human intervention studies {#Sec9}
---------------------------------------------------------------------

Female sex hormones and their receptors favour asthma developmentMale sex hormones and their receptors have a protective effect

What we can report about gender-specific symptoms {#Sec10}
-------------------------------------------------

### Female gender {#Sec11}

Pronounced asthma symptoms subject to menstruation, pregnancy, menopausePerimenstrual asthma seems to be caused/affected by dynamic changes of oestrogen levels rather than by absolute levelsHigher susceptibility to cigarette smoke-, migraine-, and VCD-related asthma or asthma-like symptomsLower asthma-related quality of life

### Male gender {#Sec12}

Pronounced age-dependent decrease in bronchial hyperreactivitySuffer more often from nocturnal symptoms and nasal polypsShow higher markers of eosinophilic airway inflammation

What we can report about gender aspects in therapy {#Sec13}
--------------------------------------------------

### Female gender {#Sec14}

Asthma often underdiagnosedRisk factor for asthma exacerbationsHigher responsiveness to leukotriene antagonists during puberty

### Male gender {#Sec15}

Lower therapeutic adherenceHigher responsiveness to inhaled steroids and leukotriene antagonists (the latter only during childhood)

Conclusion and future perspectives {#Sec16}
==================================

Different susceptibility to asthma does exist in males and females, with increased asthma prevalence and severity in adult women. However, the role of male and female sex hormones in asthma pathogenesis is not entirely elucidated. These gender differences in asthma exemplify that distinguishing different asthma phenotypes is a complex process, which should not be replaced by simple endotyping algorithms using few molecular or cellular parameters only.

DHEA

:   Dehydroepiandrosterone

FEV

:   Forced expiratory volume

FVC

:   Forced vital capacity

ILO

:   Inducible laryngeal obstruction

PMA

:   Pre- or perimenstrual asthma

VCD

:   Vocal cord dysfunction
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